BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00377-0. [PMID: 34856198 DOI: 10.1016/S2468-1253(21)00377-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Li M, Yao L, Wang Q, Wang X, Yang K. Ranking treatments in the network meta-analysis should consider the certainty of evidence. The Lancet Gastroenterology & Hepatology 2022;7:287-8. [DOI: 10.1016/s2468-1253(21)00470-2] [Reference Citation Analysis]
2 Rowan C, Ungaro R, Mehandru S, Colombel JF. An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis. Expert Opin Pharmacother 2022. [PMID: 35503955 DOI: 10.1080/14656566.2022.2071605] [Reference Citation Analysis]
3 Ma C, Choi MY. Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00432-5. [PMID: 34856197 DOI: 10.1016/S2468-1253(21)00432-5] [Reference Citation Analysis]
4 Napolitano M, D'amico F, Ragaini E, Peyrin-biroulet L, Danese S. Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy. DDDT 2022;Volume 16:1897-913. [DOI: 10.2147/dddt.s340459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Crispino F, Grova M, Bruno EM, Monachino N, Rizzo G, Casà A, Renna S, Macaluso FS, Orlando A. Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets. Drugs 2022. [PMID: 35900700 DOI: 10.1007/s40265-022-01750-y] [Reference Citation Analysis]
6 Hanzel J, Hulshoff MS, Grootjans J, D'Haens G. Emerging therapies for ulcerative colitis. Expert Rev Clin Immunol 2022. [PMID: 35477319 DOI: 10.1080/1744666X.2022.2069562] [Reference Citation Analysis]
7 Pugliese D, Privitera G, Fiorani M, Parisio L, Calvez V, Papa A, Gasbarrini A, Armuzzi A. Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab. Therap Adv Gastroenterol 2022;15:17562848221102283. [PMID: 35721840 DOI: 10.1177/17562848221102283] [Reference Citation Analysis]
8 Lasa JS, Olivera PA, Peyrin-biroulet L. Ranking treatments in the network meta-analysis should consider the certainty of evidence – Authors' reply. The Lancet Gastroenterology & Hepatology 2022;7:288. [DOI: 10.1016/s2468-1253(22)00018-8] [Reference Citation Analysis]